Innosuisse logo

Innosuisse

Europe, Bern, Switzerland, Berne

Description

Innosuisse is the Swiss Innovation Agency, a federal entity under public law, dedicated to fostering science-based innovation across Switzerland. Its core mission is to bridge the gap between scientific research and its practical application in industry and society. Unlike traditional venture capital firms, Innosuisse does not engage in equity investments. Instead, it operates primarily through grants, interest-free loans, and comprehensive coaching programs, aiming to stimulate economic growth and enhance Switzerland's competitive edge in global innovation.

The agency offers a diverse portfolio of support instruments tailored to different stages and types of innovation. A significant component involves funding "Innovation Projects," which are collaborative R&D initiatives between companies or organizations and research institutions. Innosuisse typically covers up to 50% of the eligible project costs for these ventures. For emerging enterprises, the agency provides "Start-up Coaching" to guide young entrepreneurs, and critically, "Start-up Loans" specifically targeting deep-tech startups. These interest-free loans are designed to provide crucial early-stage capital.

Innosuisse demonstrates a substantial commitment to the Swiss innovation ecosystem. According to its 2022 annual report, the agency approved 508 new innovation projects, committing a total of CHF 200.7 million in funding. This highlights its significant role in supporting collaborative research and development efforts. Furthermore, Innosuisse actively supports the burgeoning startup scene; in 2022, it provided interest-free loans to 100 deep-tech startups, with the total disbursed amount for these loans reaching CHF 15 million. These loans are structured to provide up to CHF 150,000 per startup, offering vital non-dilutive capital.

While Innosuisse's larger innovation project grants can involve substantial sums, the most direct "first cheque" equivalent for a startup from Innosuisse comes in the form of these interest-free loans. The agency explicitly states that these loans are provided "up to CHF 150,000." Given that 100 startups received a total of CHF 15 million in 2022, it indicates that each of these supported startups received the maximum amount. Therefore, the typical first cheque for deep-tech startups is consistently at this upper limit.

Investor Profile

Innosuisse has backed more than 172 startups, with 11 new investments in the last 12 months alone. The firm has led 137 rounds, about 80% of its total and boasts 7 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Grant, Pre Seed, Seed rounds (top funding stages).
  • Majority of deals are located in Switzerland, United States, United Kingdom.
  • Strong thematic focus on Health Care, Biotechnology, Medical Device.
  • Led 9 rounds in the past year.
  • Typical check size: $168K.

Stage Focus

  • Grant (93%)
  • Pre Seed (5%)
  • Seed (2%)
  • Series Unknown (1%)

Country Focus

  • Switzerland (92%)
  • United States (4%)
  • United Kingdom (2%)
  • South Korea (1%)
  • France (1%)
  • Taiwan (1%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical Device
  • Software
  • Manufacturing
  • Artificial Intelligence (Ai)
  • Medical
  • Machine Learning
  • Pharmaceutical
  • Renewable Energy
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Innosuisse frequently co-invest with?

CRV
North America, California, United States, Palo Alto
Co-Investments: 1
MassChallenge
North America, Massachusetts, United States, Boston
Co-Investments: 1
Venture Kick
Europe, Zurich, Switzerland, Schlieren
Co-Investments: 2
E
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 3
Innovate UK
Europe, Wiltshire, United Kingdom, Swindon
Co-Investments: 4
Korea Institute for Advancement of Technology
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 2
European Innovation Council
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 2
F
Europe, Geneve, Switzerland, Geneva
Co-Investments: 1
H2
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 3
Gebert Rüf Stiftung
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2

Which angels does Innosuisse often collaborate with?

Ryan Gariepy
North America, Ontario, Canada, Kitchener
Shared Deals: 1
Shared Deals: 1
TK
North America, California, United States, San Francisco
Shared Deals: 1
TR
Europe, Niedersachsen, Germany, Hanover
Shared Deals: 1
DK
Europe, Hessen, Germany, Bergheim
Shared Deals: 1

What are some of recent deals done by Innosuisse?

Aldena Therapeutics

Boston, Massachusetts, United States

Aldena Therapeutics is a private biotech startup that invented siRNA-based treatments for dermatological conditions.

BiotechnologyTherapeutics
GrantJun 25, 2025
Amount Raised: $656,221
Encelta

Basel, Basel-Stadt, Switzerland

Encelta T-cell therapy target and eliminate both blood cancers and solid tumors combined with bispecific antibodies.

BiopharmaBiotechnologyHealth Care
GrantMay 19, 2025
Amount Raised: $1,700,000
Adoram Therapeutics

Swiss, West Virginia, United States

Adoram Therapeutics is a company that uses the benefits of allosteric biochemistry to develop novel therapies.

BiopharmaBiotechnologyMedical
GrantMay 5, 2025
Amount Raised: $1,277,113
OncoSwab

San Francisco, California, United States

OncoSwab is creating a point-of-care test to detect lung cancer in high-risk individuals.

BiotechnologyHealth Care
GrantMay 2, 2025
Amount Raised: $1,572,702
Manukai

Zürich, Zurich, Switzerland

Manukai, an ETH Zurich spin-off, creates novel AI models to unlock the value of production data in metal machining.

CADMachine LearningManufacturingSoftware
Pre SeedMar 31, 2025
Amount Raised: $3,000,000
Vestir AI

Zug, Zug, Switzerland

Revolutionizing online clothes shopping through AI-powered digital avatar technology

GrantNov 21, 2024
Amount Raised: $534,812
Ymmunobio

Basel, Basel-Stadt, Switzerland

Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments.

BiotechnologyMedicalProduct Research
GrantNov 8, 2024
Csky.ai

Prilly, Vaud, Switzerland

Csky.ai specializes in using Edge AI technologies to enrich even the most sensitive discussions.

Artificial Intelligence (AI)Cyber SecurityHealth CareInformation ServicesInformation TechnologyMachine LearningMeeting Software
GrantNov 1, 2024
Amount Raised: $1,387,444
LatticeFlow

Zürich, Zurich, Switzerland

LatticeFlow is empowering organizations to build and deploy robust AI they can understand and trust.

Artificial Intelligence (AI)Computer VisionEnterprise SoftwareMachine Learning
GrantOct 24, 2024
Amount Raised: $3,000,000
Picterra

Ecublens, Vaud, Switzerland

Geospatial ML SaaS platform for Earth Observation imagery

AerospaceArtificial Intelligence (AI)Computer VisionDronesGeospatialInformation TechnologyMachine LearningSaaSSoftware
GrantOct 7, 2024